Form 4 for LGND LIGAND PHARMACEUTICALS INC

Accepted 2025-04-16 00:00:00 ET · period of report 2025-04-01 · accession 0001104659-25-035352 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2025-04-16	2025-04-01	LGND	Sabba Stephen L	Dir	M - OptEx	$52.30	+2,406	32.6K	+8%	+$125.8K
D	2025-04-16	2025-04-01	LGND	Sabba Stephen L	Dir	M - OptEx	$0.00	-2,406	0	-100%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-04-01	M	A	2,406	$52.30	32,584	D	—	—	(F1) These securities, as represented in Column 5, includes the grant of 1,252 restricted shares approved by the Board of Directors of the Company at the Annual Meeting held June 14, 2024, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date (such meeting has not yet been held) or (b) on the first anniversary of the grant date, as reported on the Reporting Person's Form 4, dated 25 June 2024, which was filed to reflect the 2024 Meeting grant.
2	Derivative	Non-Qualified Stock Option (right to buy)	2025-04-01	M	D	2,406	$0.00	0	D	$52.30 · — to 2025-04-24	2,406 Common Stock	(F2) These securities, as represented in Column 5, were acquired by a grant of 2,754 shares approved by the Board of Directors of the Company at the 2015 Meeting, as previously reported on the Reporting Person's Form 4, dated 28 April 2015. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time. The original grant was adjusted to 2,406 shares and the exercise price adjusted to $52.30 pursuant to the OmniAb Inc. separation from the Company.